Artelo Biosciences
ARTL
2 hedge funds and large institutions have $35.7K invested in Artelo Biosciences in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0.03% more ownership
Funds ownership: 0.77% → 0.8% (+0.03%)
4% less capital invested
Capital invested by funds: $37.2K → $35.7K (-$1.51K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$185 |
| 2 |
Wells Fargo
San Francisco,
California
|
-$37 |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$1 |
ARTL Hedge Fund Activity: Q2 2024 in Review
2 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2024, worth a combined $35.7K — down 4.1% from $37.2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.35K. The largest seller was UBS Group, exiting entirely with an estimated $185 sold.
- 2 institutional investors held Artelo Biosciences (ARTL) as of Q2 2024, down from 3 in Q1 2024.
- Funds reported $35.7K of Artelo Biosciences stock for Q2 2024, down 4.1% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q2 2024 was Tower Research Capital (TRC), an estimated $1.35K added.
- The largest Artelo Biosciences seller in Q2 2024 was UBS Group, an estimated $185 sold.
Based on aggregated 13F filings for Q2 2024.